Holen Sie sich die Stockscreener-App
425.94
1.04%
4.34
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$421.60
Offen:
$423.74
24-Stunden-Volumen:
76,006
Relative Volume:
0.21
Marktkapitalisierung:
$9.44B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-16.96
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
+0.50%
1M Leistung:
-7.12%
6M Leistung:
+27.57%
1J Leistung:
+97.28%
1-Tages-Spanne:
$420.50
$430.00
1-Wochen-Bereich:
$393.61
$436.84
52-Wochen-Spanne:
$238.04
$463.62
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
425.38 | 9.40B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
418.30 | 106.97B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.30 | 68.62B | 14.25B | 4.58B | 3.56B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.43 | 63.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
819.09 | 50.61B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.99 | 35.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Emerald Advisers LLC Acquires 5,199 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Grants Equity Awards to New Employees Under 2025 Inducement Plan - MyChesCo
Is it too late to sell Madrigal Pharmaceuticals Inc.Forecast Cut & Fast Entry High Yield Tips - newser.com
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by D.A. Davidson & CO. - MarketBeat
How strong is Madrigal Pharmaceuticals Inc. (YDO1) stock earnings growthWeekly Investment Report & Verified Momentum Watchlists - newser.com
Can Madrigal Pharmaceuticals Inc. stock hit record highs againIndex Update & Free Community Supported Trade Ideas - newser.com
How forex fluctuations impact Madrigal Pharmaceuticals Inc. (YDO1) stockTrade Ideas & AI Enhanced Trading Signals - newser.com
Using RSI to spot recovery in Madrigal Pharmaceuticals Inc.Long Setup & Accurate Technical Buy Alerts - newser.com
Madrigal Pharmaceuticals Inc. stock trendline breakdownMarket Movement Recap & Free Low Drawdown Momentum Trade Ideas - newser.com
How Madrigal Pharmaceuticals Inc. stock reacts to global recession fearsMarket Activity Summary & Weekly High Return Stock Forecasts - newser.com
How to escape a deep drawdown in Madrigal Pharmaceuticals Inc.Weekly Gains Report & Community Verified Trade Alerts - newser.com
Is Madrigal Pharmaceuticals Inc. trending in predictive chart modelsEarnings Trend Report & Technical Buy Zone Confirmation - newser.com
Madrigal Pharmaceuticals Experiences Evaluation Revision Amid Strong Market Performance - Markets Mojo
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025 - The Manila Times
Madrigal Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Rallies & Real-Time Market Trend Scan - newser.com
Madrigal (NASDAQ: MDGL) to present cirrhosis and real-world Rezdiffra data at AASLD 2025 - Stock Titan
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep raising dividendsBond Market & Capital Efficiency Focused Ideas - newser.com
Chart based exit strategy for Madrigal Pharmaceuticals Inc.Quarterly Investment Review & Precise Buy Zone Identification - newser.com
Statistical indicators supporting Madrigal Pharmaceuticals Inc.’s strengthTrade Signal Summary & Expert Approved Momentum Ideas - newser.com
How to integrate Madrigal Pharmaceuticals Inc. into portfolio analysis toolsMarket Risk Summary & Reliable Intraday Trade Alerts - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock profit from AI boom2025 Earnings Impact & Daily Chart Pattern Signals - Fundação Cultural do Pará
Madrigal Pharmaceuticals set to unveil Q3 2025 financial results on November 4 - Traders Union
Madrigal Pharmaceuticals (NASDAQ:MDGL) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Is Madrigal Pharmaceuticals Inc a good long term investmentProtective Put Strategies & Unlock Free Weekly Portfolio Checkups - earlytimes.in
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):